Stay updated with breaking news from Executive Stephan Jackman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Dean Seal Alzamend Neuro has gotten the go-ahead from federal regulators to launch a clinical study of its treatment for major depressive disorder. The biopharmaceutical company said...
By Michael Dabaie Alzamend Neuro Inc. shares rose 10% to $2.79 Friday after the company said it received positive topline data from a Phase 1 clinical trial for AL001 in dementia related to... | December 17, 2021